RC48-ADC plus immunotherapy for advanced scrotal Paget disease
Part of Cancer clinical trials.
This trial tests a combination of two drugs (RC48-ADC and JS001) for advanced scrotal Paget disease that has spread or cannot be removed by surgery. The goal is to see if this treatment can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- Your tumor must test positive for HER2 (at least 1+ score).
- You must have at least one tumor that can be measured on a CT scan or seen on the skin.
- Your overall health should be good (ECOG score 0 or 1).
- Your blood counts, liver, and kidney function must meet certain minimum levels.
- You must not have a history of autoimmune disease requiring treatment in the past 2 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs: disitamab vedotin (which attacks cancer cells with a certain protein) and bicalutamide (which blocks male hormones that can fuel cancer growth). It is for people with Paget's disease that has spread or cannot be removed, and whose cancer cells have specific protein markers called HER2 and AR.
This trial tests a combination of three chemotherapy drugs (albumin-paclitaxel, ifosfamide, and cisplatin) for people with certain rare cancers that have spread to other parts of the body (stage IV). It looks at how well the treatment works and if it is safe.
This trial tests an investigational drug called Disitamab Vedotin for people with advanced Paget's disease that tests positive for HER2. It aims to see if the drug can shrink tumors or improve skin lesions.
This trial tests a new combination treatment for advanced penile cancer that hasn't been treated before. It combines a targeted drug (becotatug vedotin) designed to attack cancer cells with an immunotherapy drug (pucotenlimab) that helps your immune system fight cancer.
This trial tests a combination of two drugs—disitamab vedotin (a targeted antibody-drug that attacks HER2-positive cancer cells) and abiraterone (a hormone therapy)—to see if they can slow or shrink prostate cancer that has spread and become resistant to standard treatments.
This trial tests a combination of two treatments for advanced prostate cancer that has stopped responding to hormone therapy. One treatment is a targeted radiation therapy (177Lu-PSMA-617) and the other is an immunotherapy (sipuleucel-T) that helps your immune system fight the cancer.
Hear when a new Paget Disease, Extramammary trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.